Vor biopharma announces collaboration with janssen to develop engineered hematopoietic stem cell transplants combined with a bi-specific antibody therapy for acute myeloid leukemia (aml)

Cambridge, mass., july 08, 2021 (globe newswire) -- vor biopharma (nasdaq: vor or the company), a cell therapy company pioneering engineered hematopoietic stem cell (ehsc) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a collaboration with janssen biotech, inc. (“janssen”), one of the janssen pharmaceutical companies of johnson & johnson. the agreement was facilitated by johnson & johnson innovation.
VOR Ratings Summary
VOR Quant Ranking